Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC

Congress Newsletter 2021

EA21 Newsletter: Session 12D2 Pro-Con debate: Tranexamic acid for all bleeding patients in the perioperative setting

Sunday December 19, 11:00 – 12:00 – Channel 4

The pro stance in this debate will be presented by Beverley Hunt, Professor of Thrombosis & Haemostasis, Kings College London, Consultant at Guy’s and St Thomas’ NHS Foundation Trust, London and Medical Director of Thrombosis UK.

Prof Hunt will say: “Tranexamic acid (TXA) is a wonderful drug for in multiple large randomised controlled trials when used in low dose and for 8 hours or less, it reduced death due to bleeding by about a third in trauma, post-partum haemorrhage and perioperatively without increasing thrombotic risk.”

Moreover, she explains that in bleeding patients it reduces bleeding by about 30%, which means the use of transfusion is cut, and operation times and length of stay will tend to be shorter. “However to say that it should be used in all surgical procedures is a step too far,” she says. “Firstly it only needs to be used when there is a risk of excessive bleeding: the UK’s National Institute for Health and Care Excellence (NICE) suggests it should be used if > 500mls of blood loss is expected and this seems a sensible cut-off. It is not without its side effects, trials of larger doses and/or used for longer periods of time have shown increased fits and some increase in thrombotic risk. It should not be used in those with haematuria or disseminated intravascular coagulation.”

Prof Hunt concludes: “In summary, we are in a good place with TXA, it is excellent at reducing bleeding when used in low dose and is very safe in this setting.”

The con position in the debate will be presented by Professor Marc Maegele, Cologne-Merheim Medical Center (CMMC), University Witten/Herdecke, Germany.

He will discuss how the results from the CRASH-2, CRASH-3 and WOMAN randomized controlled trials (RCTs) have influenced major clinical guidelines for the treatment of acute bleeding in various settings and have also prompted a rather uncritical use of the antifibrinolytic tranexamic acid (TXA) across a range of indications.

He says: “Subsequent studies, mostly retrospective though, could not reproduce these positive findings and two most recent RCTs on the prehospital use of TXA in patients at risk of haemorrhage or moderate to severe TBI could not find a difference in outcomes versus placebo. Vice-versa, a recent single-centre RCT on the effect of early intravenous two and four-gram bolus dosing of TXA versus placebo showed a dose-dependent increase in thromboembolic events. Substantial uncertainties and knowledge gaps in the clinical use of TXA remain.”

Read More of our special newsletter covering our virtual congress